Pancreatic cancer could be treated with a Parkinson's drug
The new research suggests that carbidopa, which is a drug approved by the Food and Drug Administration (FDA) and widely used to treat Parkinson's disease, has significant anti-cancer properties.
Carbidopa is typically used in conjunction with levodopa (L-Dopa) to treat Parkinson's disease. And previous studies have shown that patients with Parkinson's tend to have a lower incidence of cancer.
In older research, scientists investigated whether or not it was the drug L-Dopa that yielded the anti-cancer effect, but they did not find any significant results.
So now, a team led by Dr. Yangzom Bhutia - from the Texas Tech University Health Sciences Center (TTUHSC) in Lubbock - hypothesized that carbidopa alone could have anti-cancer properties.
Commenting on the motivation for the research, Dr. Bhutia says, "Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon."
"Carbidopa is never used by itself as a drug for any disease," she adds. "But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."
The first author of the study is Jiro Ogura, of the Department of Cell Biology and Biochemistry at TTUHSC, and the findings were published in the Biochemical Journal.
Article originally published in Medical News Today, www.medicalnewstoday.com.
To read full article, please visit https://www.medicalnewstoday.com/articles/319578.php.
Related Stories
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
Willed Body Memorial Service Honors Those Who Donated
On Memorial Day each May, a service is conducted at the Texas Tech University Health Sciences Center Institute of Anatomical Sciences to pay respect to the Willed Body Program donors and their families.
Molecular Pathology Preceptorship: Unmatched Value and Experience
Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.
Recent Stories
Legislative Support Strengthens Texas Tech University Health Sciences Center’s Efforts to Improve Rural Cancer Care
Support for TTUHSC continued in the 89th legislative session, including $25 million to establish the Rural Cancer Collaborative.
TTUHSC’s Affordable Medical Education Empowers West Texas Students to Serve
On Friday, July 25, students marked a defining moment in their journey at the White Coat Ceremony, symbolizing not only the start of their medical education but also their dedication to the communities that shaped them.
Transformative, Collaborative Gift to Accelerate Research on Urinary Tract Infections
Eliese Teasdale recently made a $975,000 gift to the TTUHSC School of Nursing to support ongoing research focusing on detection and treatment of urinary tract infections (UTIs) in women.